ARTHEx Biotech Receives FDA Fast Track Designation for New DM1 Treatment ARTHEx Biotech has received Fast Track designation for ATX-01, an innovative RNA therapeutic aimed at treating Myotonic Dystrophy type 1, addressing a significant unmet medical need.

ARTHEx Biotech Receives FDA Fast Track Designation for New DM1 Treatment #Spain #Myotonic_Dystrophy #Valencia #ARTHEx_Biotech #ATX-01

ARTHEx Biotech's Research Unveils Promising Treatment for Myotonic Dystrophy Type 1 ARTHEx Biotech published groundbreaking findings on ATX-01 for Myotonic Dystrophy Type 1, revealing its potential as a transformative therapy.

ARTHEx Biotech's Research Unveils Promising Treatment for Myotonic Dystrophy Type 1 #Spain #Myotonic_Dystrophy #Valencia #ARTHEx_Biotech #ATX-01

ARTHEx Biotech Engages Investors with Upcoming Industry Events Participation ARTHEx Biotech S.L. is set to engage with investors at key events focusing on innovative RNA medicine for rare diseases. Key executives will share insights.

ARTHEx Biotech Engages Investors with Upcoming Industry Events Participation #Spain #Myotonic_Dystrophy #Valencia #ARTHEx_Biotech #RNA_Medicines

ARTHEx Biotech Boosts Series B Round to $87M for Breakthrough RNA Medicine Development ARTHEx Biotech has successfully increased its Series B financing to $87 million, advancing the clinical development of its lead program ATX-01 for Myotonic Dystrophy Type 1.

ARTHEx Biotech Boosts Series B Round to $87M for Breakthrough RNA Medicine Development #Spain #Valencia #ARTHEx_Biotech #ATX-01 #RNA_Medicines

ARTHEx Biotech Set to Participate in 2025 Jefferies Global Healthcare Conference ARTHEx Biotech S.L. will showcase its innovative gene modulation medicines at the 2025 Jefferies Global Healthcare Conference from June 3-5.

ARTHEx Biotech Set to Participate in 2025 Jefferies Global Healthcare Conference #Spain #Valencia #ARTHEx_Biotech #ATX-01 #gene_modulation

ARTHEx Biotech Joins the 24th Annual Needham Virtual Healthcare Conference ARTHEx Biotech will be participating in the Needham Virtual Healthcare Conference, highlighting its innovative gene modulation therapies aimed at treating rare illnesses.

ARTHEx Biotech Joins the 24th Annual Needham Virtual Healthcare Conference #Spain #Myotonic_Dystrophy #Valencia #ARTHEx_Biotech #ATX-01